Business Context and Reporting Period
Company: Amphastar Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: May 9, 2016
Reporting Period: Quarter ended March 31, 2016
This filing serves as a notification that the company issued a press release announcing its financial results for the first quarter of 2016. The detailed financial data is contained within the attached press release (Exhibit 99.1) and is not embedded directly in the text of this 8-K form.
Key Financial Metrics
The text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the press release furnished as Exhibit 99.1.
Material Changes
No material changes or comparative financial data are disclosed within the body of this filing. The document solely references the issuance of the quarterly results announcement.
Guidance, Outlook, and Risks
Management Commentary: The filing notes the issuance of a press release by management regarding Q1 2016 results but does not summarize the commentary, guidance, or outlook contained therein.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Legal Disclaimer: The filing explicitly states that the information in the press release (Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 9, 2016) for actual revenue, net income, and EPS figures.
- Verify year-over-year growth rates and margin trends in the attached press release.
- Check for any updated forward-looking guidance or operational milestones mentioned in the press release.
- Confirm the status of the company's cash position and debt obligations as detailed in the full earnings release.